Quarterly ResultMay 14, 2026, 04:21 PM
MediciNova Q1 Net Loss Narrows to $2.59M; Revenue $186,984
AI Summary
MediciNova reported a net loss of $2.59 million for the first quarter of 2026, an improvement from a $2.86 million net loss in the prior year. The company generated $186,984 in revenue, primarily from clinical research services for MN-166 (ibudilast) in ALS, compared to no revenue in the same period last year. Operating expenses decreased, contributing to a reduced operating loss. The company also terminated its ATM agreement and has new equity distribution agreements in place, though no shares were sold under them in Q1 2026.
Key Highlights
- Net loss for Q1 2026 narrowed to $2.59 million from $2.86 million in Q1 2025.
- Generated $186,984 in revenue in Q1 2026, up from $0 in Q1 2025.
- Operating loss improved to $2.84 million in Q1 2026 from $3.20 million in Q1 2025.
- Cash and cash equivalents stood at $27.3 million as of March 31, 2026.
- Research, development, and patent expenses decreased to $1.26 million from $1.84 million.
- The ATM agreement was terminated effective March 8, 2026.
- New Standby Equity Purchase Agreement for up to $30.0 million and Equity Distribution Agreement for up to $50.0 million are in place.
- Future potential milestone payments total $26.5 million for product candidates.